^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GMF-1A3
i
Other names: GMF-1A3
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gundersen Medical Foundation
Drug class:
Microtubule inhibitor, Cleaved amphiregulin-targeted antibody-drug conjugate
Related drugs:
1year
Anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate targeting cell surface cleaved Amphiregulin in breast cancer (AACR 2023)
We further demonstrate that these antibodies recognize the Amphiregulin neo-epitope in formalin fixed paraffin embedded tumor tissue, suggesting their utility as a companion diagnostic for patient selection. A pan-cancer tissue microarray analysis indicates that the target is commonly detected (> 50% of cases) in breast, prostate, liver and lung cancer.
Clinical
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • ADAM17 (ADAM Metallopeptidase Domain 17)
|
GMF-1A3
Share via
